Scientific Letters
Vol. 12 No. 1 (2020): Mediterranean Journal of Hematology and Infectious Diseases, Volume 12, 2020
https://doi.org/10.4084/mjhid.2020.065

Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study

Ceftolozane-Tazobatam for febrile neutropenia

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: June 18, 2020
Accepted: August 8, 2020
Published: 2020-08-29 — Updated on 2020-09-07

Versions

7942
Views
693
Downloads
193
HTML
Ceftolozane-Tazobactam, febrile neutropenia, hematologic malignancy, carbapenem-sparing

Authors

Francesco Marchesi
francesco.marchesi@ifo.gov.it
Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy Tel: +39 06 52665022 Fax: +39 06 52662849 E-mails: ; fmarchesi@ifo.it, Italy.
Fabrizio Ensoli
IRCCS San Gallicano Dermatological Institute, Italy.
Irene Terrenato
IRCCS Regina Elena National Cancer Institute, Italy.
Elena Papa
IRCCS Regina Elena National Cancer Institute, Italy.
Fulvia Pimpinelli
IRCCS San Gallicano Dermatological Institute, Italy.
Grazia Prignano
IRCCS San Gallicano Dermatological Institute, Italy.
Antonio Spadea
IRCCS Regina Elena National Cancer Institute , Italy.
Ilaria Cavallo
IRCCS San Gallicano Dermatological Institute, Italy.
Enea Gino Di Domenico
IRCCS San Gallicano Dermatological Institute, Italy.
Luigi Toma
IRCCS Regina Elena National Cancer Institute, Italy.
Andrea Mengarelli
IRCCS Regina Elena National Cancer Institute, Italy.

NA

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, et al; SEIFEM Group. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97:1717-1726. doi: 10.1007/s00277-018-3341-6.
Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, et al; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI). Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin Infect Dis. 2017;65:1884-1896. doi: 10.1093/cid/cix690.
Verlinden A, Mikulska M, Knelange NS, Averbuch D, Styczynski J; Infectious Diseases Working Party (IDWP) of the European Group for Blood and Marrow Transplantation Group (EBMT) Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant. 2020 Feb 11. doi: 10.1038/s41409-020-0811-y [Epub ahead of print].
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign:International guidelines for management of sepsis and septic shock, 2016. Intensive Care Med. 2017;43:304-377. doi: 10.1007/s00134-017-4683-6.
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051. doi: 10.1200/JCO.2000.18.16.3038.
Marchesi F, Cattaneo C, Criscuolo M, Delia M, Dargenio M, Del Principe MI, et al.; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group. A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: a prospective multicenter study of the SEIFEM group. Am J Hematol. 2019;94:1104-1112. doi: 10.1002/ajh.25585.
Di Domenico EG, Rimoldi SG, Cavallo I, D'Agosto G, Trento E, Cagnoni G, et al. Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis. BMC Microbiol. 2019;19:228. doi: 10.1186/s12866-019-1596-2.
Karaiskos I, Giamarellou H. Carbapenem-sparing strategies for ESBL producers: when and how? Antibiotics. (Basel) 2020;9. doi: 10.3390/antibiotics9020061.
Corcione S, Lupia T, Maraolo AE, Mornese Pinna S, Gentile I, et al. Carbapenem-sparing strategy: carbapenemase, treatment, and stewarship. Curr Opin Infect Dis. 2019;32:663-673. doi: 10.1097/QCO.0000000000000598.
Fernández-Cruz A, Alba N, Semiglia-Chong MA, Padilla B, Rodríguez-Macías G, Kwon M, et al. A case-control study of real-life experience of ceftolozane-tazabactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2019;63(2):e02340-18. doi: 10.1128/AAC.02340-18.

Ethics Approval

None

Supporting Agencies

None

How to Cite



“Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study: Ceftolozane-Tazobatam for febrile neutropenia” (2020) Mediterranean Journal of Hematology and Infectious Diseases, 12(1), p. e2020065. doi:10.4084/mjhid.2020.065.
Copyright (c) 2020 Francesco Marchesi, Luigi Toma, Enea Gino Di Domenico, Ilaria Cavallo, Antonio Spadea, Grazia Prignano, Fulvia Pimpinelli, Elena Papa, Irene Terrenato, Fabrizio Ensoli, Andrea Mengarelli Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.